UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population

详细信息    查看全文

• 作者：Nancy Hakooz (12) nhakooz@ju.edu.jo
  Sameh Alzubiedi (1) s.alzubiedi@ju.edu.jo
  Al-Motassem Yousef (1) ayousef@ju.edu.jo
  Tawfiq Arafat (3) tawfiqarafat@yahoo.com
  Rana Dajani (4) rdajani@hu.edu.jo
  Nidaa Ababneh (5) nida2080@yahoo.com
  Said Ismail (5) sismail@ju.edu.jo
• 关键词：Drug metabolism – ; UGT1A4 – ; Jordanian population – ; Polymorphism
• 刊名：Molecular Biology Reports
• 出版年：2012
• 出版时间：July 2012
• 年：2012
• 卷：39
• 期：7
• 页码：7763-7768
• 全文大小：203.9 KB
• 参考文献：1. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41(2):89–295
  2. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59(4):303–312
  3. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype–phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63(6):537–546
  4. Djaffar-Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N (2011) Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. Genet Test Mol Biomarkers 15(11):827–830
  5. Zalloum I, Hakooz N, Arafat T (2011) Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep. doi:10.1007/s11033-011-1204-5
  6. Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N (2011) Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 38(8):5449–5452
  7. Rais N, Chawla YK, Kohli KK (2006) CYP3A phenotypes and genotypes in North Indians. Eur J Clin Pharmacol 62(6):417–422
  8. Bae JW, Choi CI, Lee JH, Jang CG, Chung MW, Lee SY (2011) Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Eur J Clin Pharmacol 67(1):39–45
  9. Moini M, Ghaderi F, Sagheb MM, Tavasolli AR, Azarpira N, Darai M, Geramizadeh B (2011) The frequency and distribution of thiopurine S-methyltransferase alleles in south Iranian population. Mol Biol Rep. doi:10.1007/s11033-011-1248-6
  10. Hakooz N, Arafat T, Payne D, Ollier W, Pushpakom S, Andrews J, Newman W (2010) Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population. Eur J Clin Pharmacol 66(10):999–1003
  11. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D’Alessandro N (2011) Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on patients. Int J Mol Med 28(6):1093–1102
  12. Zhang J, Zhang X, Liu L, Tong W (2010) Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients. Transplant Proc 42(9):3459–3464
  13. Azarpira N, Ashraf MJ, Khademi B, Darai M, Hakimzadeh A, Abedi E (2011) Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma. Mol Biol Rep 38(8):5443–5448
  14. B’Chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S (2009) CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci 84(21–22):779–784
  15. Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616
  16. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8(4):R50
  17. Ogura K, Ishikawa Y, Kaku T, Nishiyama T, Ohnuma T, Muro K, Hiratsuka A (2006) Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 71(9):1358–1369
  18. Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D (2009) Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci 1155:99–111
  19. Tukey RH, Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59(3):405–414
  20. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15(10):677–685
  21. Wiener D, Fang JL, Dossett N, Lazarus P (2004) Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64(3):1190–1196
  22. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP (2004) Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39(4):970–977
  23. Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, Guillemette C (2009) A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics 19(12):945–954
  24. Menard V, Girard H, Harvey M, Perusse L, Guillemette C (2009) Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat 30(4):677–687
  25. Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 33(5):672–675
  26. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Shirao K, Tamura T, Yamamoto N, Kunitoh H, Hamaguchi T, Yoshida T, Kubota K, Ohtsu A, Muto M, Minami H, Saijo N, Kamatani N, Sawada JI (2006) Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 6(1):63–75
  27. Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, Ozawa S, Kawamoto M, Kamatani N, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Sawada J (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20(2):144–151
  28. Yea SS, Lee SS, Kim WY, Liu KH, Kim H, Shon JH, Cha IJ, Shin JG (2008) Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 30(1):23–34
  29. Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J (2006) Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 27(7):717
  30. Brooker R (2005) Genetics, analysis and principles, 2nd edn. McGraw-Hill, New York
  31. http://www.graphpad.com/quickcalcs/chisquared1.cfm
  32. Banerjee B, Saha N, Daoud ZF, Khalaf FH, Qudah H (1981) A genetic study of the Jordanians. Hum Hered 31(2):65–69
  33. Sanchez-Velasco P, Karadsheh NS, Garcia-Martin A, Ruiz de Alegria C, Leyva-Cobian F (2001) Molecular analysis of HLA allelic frequencies and haplotypes in Jordanians and comparison with other related populations. Hum Immunol 62(9):901–909
• 作者单位：1. Faculty of Pharmacy, University of Jordan, Amman, 11942 Jordan2. Faculty of Pharmacy, Zarqa University, Zarqa, 13132 Jordan3. Jordan Center for Pharmaceutical Research, Amman, 11195 Jordan4. Biology Department, Hashemite University, P.O. Box 150459, Zarqa, 13115 Jordan5. Faculty of Medicine, University of Jordan, Amman, 11942 Jordan
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Animal Anatomy, Morphology and Histology
  Animal Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-4978

文摘

Glucuronidation is one of the most important phase II metabolic pathways. It is catalyzed by a family of UDP-glucuronosyltransferase enzymes (UGTs). One of the subfamilies is UGT1A. Allele frequencies in UGT1A4 differ among ethnic groups. The aim of this study was to determine the allelic frequency of two most common defective alleles: UGT1A4*2 and UGT1A4*3 in a Jordanian population. A total of 216 healthy Jordanian Volunteers (165 males and 51 females) were included in this study. Genotyping for UGT1A4*1, UGT1A4*2 and UGT1A4*3 was done using a well established polymerase chain reaction–restriction fragment length polymorphism test. Among 216 random individuals studied for UGT1A4*2 mutation there were 26 individuals who were heterozygous, giving a prevalence of 12% and an allele frequency of 6.5%. Only one individual was homozygous for UGT1A4*2. The UGT1A4*3 mutation was detected as heterozygous in 9 of 216 individuals indicating a prevalence of 4.2% and allele frequency of 3.5%. Three individuals were homozygous for the UGT1A4*3 indicating a prevalence of 1.4%. The prevalence of UGT1A4*2 is similar to the Caucasians but different from other populations whilst the UGT1A4*3 prevalence in the Jordanian population is distinct from other populations. Our results provide useful information for the Jordanian population and for future genotyping of Arab populations in general.